Resistance of Helicobacter pylori to antibiotics: The main limitation of current proton-pump inhibitor triple therapy

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue SUPPL. 2, 1999, Pages

  Mégraud, Francis ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Clarithromycin; Eradication; H. pylori; Metronidazole; Omeprazole; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; ENZYME INHIBITOR; OMEPRAZOLE; PROTON PUMP;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MULTICENTER STUDIES; OMEPRAZOLE; PROTON PUMPS;

EID: 0033175978     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.
2. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996; 3:138-144.
3. Lind T, Mégraud F, Unge P, Bayerdörffer E, O'Morain C, Spiller R, et al. The MACH2 study - the role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies - a randomised double-blind study. Gastroenterology 1999; 116:248-253.
4. Mégraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11 (Suppl. 1):43-53.
5. Dore MP, Graham DY, Sepulveda AR. PBP-D a novel penicillin-binding protein is involved in amoxicillin resistance in Helicobacter pylori. Gastroenterology 1998; 114:A100.
6. Mégraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998; 43 (Suppl. 1):S61-S65.
7. Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, et al. H. pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86:743-750.
8. Bell GD, Bate CM, Axon ATR, Kerr GD, Green JRB, Emmas CE, et al. Addition of metronidazole to omeprazole-amoxicillin dual therapy increases the rate of H. pylori eradication: a double-blind randomized trial. Aliment Pharmacol Ther 1995; 9:513-520.
9. Lerang F, Moum B, Haug JB, Tolås P, Breder O, Aubert E, et al. Highly effective twice-daily triple therapies for H. pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997; 92:248-253.
10. Thijs JC, Van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A. One-week triple therapy with omeprazole, amoxicillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997; 11:305-309.
11. Bouchard S, Birac C, Lamouliatte H, Forestier S, Mégraud F. Correlation between the MICs of metronidazole on H. pylori strains and the outcome of a lansoprazole-amoxicilline-metronidazole therapy. Gut 1996; 39 (Suppl. 2):A6.
12. Xia HX, Keane CT, Beattle S, O'Morain CA. Standardisation of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against H. pylori. Antimicrob Agents Chemother 1994; 38:2357-2361.
13. Moayyedi P, Tompkins DS, Ragunathan PL, Axon ATR. Relevance of metronidazole resistance in predicting failure of omeprazole, clarithromycin and tinidazole to eradicate H. pylori. Gut 1996; 39 (Suppl. 2):A6.
14. Kist M, Strobel S, Fölsch UR, Kirchner T, Hahn EG, v. Kleist DH, et al. Prospective assessment of the impact of primary antimicrobial resistances on cure rate of Helicobacter pylori infection. Gut 1997; 41 (Suppl. 1):A90.
15. Yousfi MM, El-Zimaity HMT, Cole RA, Genta RM, Graham DY. Metronidazole, ranitidine and clarithromycin: combination treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther 1996; 10:119-122.
16. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. for the ACT-10 Study Group. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. Aliment Pharmacol Ther 1997; 11:943-952.
17. Lamouliatte H, The Aquitaine-Castro Association, de Mascarel A, Mégraud F, Samoyeau R. Double blind study comparing once daily versus twice daily dosage of PPI with amoxicillin-clarithromycin for H. pylori cure. Gut 1997; 41 (Suppl. 1):A93.
18. Broutet N, Guillon F, Sauty E, Lethuaire D, Mégraud F. Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France - preliminary results. Gut 1998; 43 (Suppl. 2):A11.
19. Mégraud F. A growing demand for Helicobacter pylori culture in the near future? Ital J Gastroenterol 1997; 29:574-576.